Document Detail

A primer on network meta-analysis for dental research.
Jump to Full Text
MedLine Citation:
PMID:  22919506     Owner:  NLM     Status:  PubMed-not-MEDLINE    
In the last decade, a new statistical methodology, namely, network meta-analysis, has been developed to address limitations in traditional pairwise meta-analysis. Network meta-analysis incorporates all available evidence into a general statistical framework for comparisons of all available treatments. A further development in the network meta-analysis is to use a Bayesian statistical approach, which provides a more flexible modelling framework to take into account heterogeneity in the evidence and complexity in the data structure. The aim of this paper is therefore to provide a nontechnical introduction to network meta-analysis for dental research community and raise the awareness of it. An example was used to demonstrate how to conduct a network meta-analysis and the differences between it and traditional meta-analysis. The statistical theory behind network meta-analysis is nevertheless complex, so we strongly encourage close collaboration between dental researchers and experienced statisticians when planning and conducting a network meta-analysis. The use of more sophisticated statistical approaches such as network meta-analysis will improve the efficiency in comparing the effectiveness between multiple treatments across a set of trials.
Yu-Kang Tu; Clovis Mariano Faggion
Related Documents :
22399866 - Analysis on descriptions of precautionary statements in package inserts of medicines.
22317576 - The question of the ergonomic use of virtual models.
22681406 - The immune epitope database: a historical retrospective of the first decade.
22562486 - Food for thought ... a toxicology ontology roadmap.
11448526 - Towards a cognitive niche: divergent foraging strategies resulting from limited cogniti...
2259206 - Dynamic information in uncertain and changing worlds.
Publication Detail:
Type:  Journal Article     Date:  2012-06-21
Journal Detail:
Title:  ISRN dentistry     Volume:  2012     ISSN:  2090-438X     ISO Abbreviation:  ISRN Dent     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-24     Completed Date:  2012-08-24     Revised Date:  2013-04-02    
Medline Journal Info:
Nlm Unique ID:  101560640     Medline TA:  ISRN Dent     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  276520     Citation Subset:  -    
Department of Oral Biology, Leeds Dental Institute, Leeds LS2 9JT, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): ISRN Dent
Journal ID (iso-abbrev): ISRN Dent
Journal ID (publisher-id): ISRN.DENTISTRY
ISSN: 2090-4371
ISSN: 2090-438X
Publisher: International Scholarly Research Network
Article Information
Download PDF
Copyright © 2012 Y.-K. Tu and C. M. Faggion Jr.
Received Day: 22 Month: 4 Year: 2012
Accepted Day: 8 Month: 5 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 21 Month: 6 Year: 2012
Volume: 2012E-location ID: 276520
ID: 3418651
PubMed Id: 22919506
DOI: 10.5402/2012/276520

A Primer on Network Meta-Analysis for Dental Research
Yu-Kang Tu12*
Clovis Mariano Faggion, Jr.3
1Department of Oral Biology, Leeds Dental Institute, Leeds LS2 9JT, UK
2Division of Biostatistics, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK
3Department of Oral Sciences, Faculty of Dentistry, University of Otago, P.O. Box 647, Dunedin 9054, New Zealand
Correspondence: *Yu-Kang Tu:
[other] Academic Editors: M. Del Fabbro, G. Perinetti, J. Walters, and P. Ylöstalo

1. Introduction

With the rise of evidence-based medicine movement in the last two decades, systematic reviews and meta-analyses have been widely used for synthesis of evidence on beneficial and/or harmful effects of different treatments. Results from those reviews and meta-analyses provide important information for drawing clinical guidelines and making health policy recommendations. For most clinical conditions, several interventions (which may be drugs, medical devices, surgeries, or a combination of them) are usually available, but most systematic reviews of randomised controlled trials (RCTs) tend to limit their scopes by only evaluating two active treatments or comparing one treatment to a control. Even if a systematic review evaluates multiple treatments, traditional meta-analysis can only perform pairwise comparisons.

There are several limitations to this approach [14]. For instance, suppose there are three new and more expensive treatments A, B, and C and a standard treatment D, six pair-wise metaanalyses (A-B, B-C, A–C, A–D, B–D, and C-D) may be undertaken to compare the differences for pairs of the four treatments. None or few of included RCTs in the paper would have compared all four treatments, and most RCTs compared only 2 or 3 of them. Consequently, those pairwise meta-analyses use different sets of RCTs for each comparison, and the evidence base is therefore different across all comparisons. A possible consequence is that results from multiple pairwise meta-analyses may not be consistent: for example, in three pairwise comparisons, treatment A is shown to be better than treatment B, and B better than treatment C; but A is inferior to C. Secondly, some head-to-head trials may not have been conducted yet (especially between the new treatments), so it is not possible to undertake traditional pairwise meta-analysis for these comparisons. Thirdly, because the number of studies available for pairwise comparisons is few, each meta-analysis may not have sufficient power to detect any genuine difference between treatments, yielding inconclusive results and providing no useful guidance on decision making.

In the last decade, a new statistical methodology, namely, network meta-analysis, has been developed to address those limitations [57]. Network meta-analysis incorporates all available evidence into a general statistical framework for comparisons of all available treatments. Thus, network meta-analysis may play an important role in the improvement of the decision making process by optimizing the use of the existing data. A further development in the network meta-analysis is to use a Bayesian statistical approach, which provides a more flexible modelling framework to take into account of heterogeneity in the evidence and complexity in the data structure [14].

Although systematic reviews with network meta-analysis for evidence synthesis has been published in mainstream medical journals [812], many dental researchers are still not aware of this new methodology, and, to the best of our knowledge, only a few network meta-analyses have appeared in dental journals [1316]. The aim of this paper is therefore to provide a nontechnical introduction to network meta-analysis for dental research community and raise the awareness of it. In the next sections, we first explained the rationale and assumptions behind the network meta-analysis; then, we described the statistical model for the network meta-analysis and used an example from periodontology for illustration. In the final section, we discussed a few practical issues to be considered when conducting a network meta-analysis.

2. Network Meta-Analysis

The basic rationale behind network meta-analysis is simple: suppose we have three treatments A, B, and C. Results from RCTs comparing A and B provide direct evidence on the difference in the treatment effects between A and B. In contrast, results from RCTs comparing A–C and those comparing B-C provide indirect evidence on the difference between A and B. The three treatments A, B, and C therefore form a network for treatment effect comparisons (Figure 1). Let us use dAB, dAC⁡, and dBC to denote the differences in the treatment effects for A-B, A–C, and B-C comparisons, respectively. The difference in treatment effects between A and B from indirect comparisons is therefore dAC⁡dBC = dABInd. If dAB is similar to dABInd, the direct and indirect evidence is consistent; otherwise, there is inconsistency in the evidence, that is, results from direct and indirect evidence are not the same.

2.1. Assumptions behind the Network Meta-Analysis

There are several assumptions for the network meta-analysis to yield meaningful results [14]. The first assumption is homogeneity for standard meta-analysis, that is, all A–C trials are “comparable” and all B-C trials are “comparable.” This is a universal assumption for all meta-analysis, although some heterogeneity increases the generalizability of results. However, whilst evidence may be homogeneous within a set of trials for certain pairwise comparisons, but it may not be so across sets of trials within the network. This leads us to the similarity assumption for the network meta-analysis, that is, the included trials are clinically and methodologically similar in term of key factors that modify the response to a treatment, such as patients' characteristics, study settings, lengths of followup, and outcome measurements. In other words, potential confounders for treatment effect comparisons are similarly distributed across included studies. When these two assumptions are questionable, results from direct and indirect evidence may be inconsistent, and consistency is the third assumption that will be discussed in the next section.

It has been suggested that results from the network meta-analysis may be less trustworthy than results from multiple pairwise comparisons, because indirect evidence is less reliable than direct evidence and more prone to biases [17, 18]. Whilst we agree that interpretation of results from the network meta-analysis always needs to be cautious because of potential biases, network meta-analysis is no more prone to biases that traditional meta-analysis, for instance, heterogeneity is also common in traditional meta-analysis. This is because the distinction between direct and indirect evidence is not meaningful in multiple treatments comparisons, as direct evidence for one comparison becomes indirect for some other comparisons [1, 2]. For example, trials including A and C are direct evidence for A–C comparisons, and trials including A and B are evidence for A-B comparisons, but they are also indirect evidence for B-C comparison. So the argument that results from mixed treatment comparison are less reliable than those from direct comparisons is untenable. We do agree that because the scope of a network meta-analysis is much broader than a traditional pairwise meta-analysis and a greater number of studies is included in the analysis, more resources and efforts are required to minimize potential errors and biases in the literature search, quality assessment, data analysis, and final interpretation of results [19, 20].

2.2. Inconsistency between Direct and Indirect Evidence

Consistency in direct and indirect evidence is another assumption behind network meta-analysis. Suppose results from trials comparing A with B show A is on average better than B, and trials comparing B with C show B is on average better than C, and indirect comparisons will then show A is better than C. If trials comparing A with C also show A is on average better than C, the indirect and direct evidence is consistent. However, what if direct evidence shows C is better than A? Does this contradiction mean that evidence from indirect comparisons is unreliable and should be disregarded?

If this argument is true, it implies the direct comparisons for A-B and B-C cannot be trusted either. This can be applied to all pairwise comparisons in the network. Therefore, when there is inconsistency in the direct and indirect evidence, the issue is not whether indirect comparisons are less reliable but how this inconsistency may be explained. If trials involved in the indirect comparisons have a better quality and fewer biases, results from indirect evidence may be more reliable than those from direct evidence. Heterogeneity in study protocols (e.g., doses, follow-up time, etc.), patient populations (age, underlying medical conditions, clinical settings, etc.), and methods for the assessment of outcomes is likely to be the source for inconsistency, while random variations may also cause inconsistency. Therefore, it is imperative to check consistency in evidence when undertaking network meta-analysis, and we will explain later in this paper how to conduct a simple test for checking it. Interpretation of network meta-analysis should always take inconsistency into account as the interpretation of traditional meta-analysis should take heterogeneity into account [2123]. Assessment of quality and characteristics of included trials should be undertaken for network meta-analysis; thus, heterogeneity in evidence can be explored when inconsistency occurs.

2.3. Statistical Model for Network Meta-Analysis

Different statistical approaches have been proposed in the literature for comparing multiple treatments [5, 7]. A fixed effects model assumes a common effect behind the observed effects, while a random effects model assumes that the “true” effect follows a distribution. In this section, we introduce the random effects model approach as suggested by Whitehead [24]:

[Formula ID: EEq1]
where yijk is the outcome for subject k in treatment group j in study i, u the grand mean, si the study effect, tj treatment effect, and stij interaction between study i and treatment j. The function f defines the relation between the outcome y and effects of s, t, and st. In meta-analysis, individual patient data are usually not available, and summary statistics for treatment effect, such as means or odds, are used instead. Therefore, (1) can be rewritten as
[Formula ID: EEq2]
where θij is the treatment effects for treatment j in the study i. For example, θij may be mean probing pocket depth reduction, or log odds for dental implant failure in 3-year followup. The interpretation of (2) is that the average treatment effect for all treatments is u, and for a specific treatment arm j in one study, its treatment effects depends on the study where it is applied (i.e., study characteristics affect the performance of all treatments in that specific study), treatment (treatments have different genuine effects), and the interaction between study and treatment (the effect of treatment j varies across studies). This model may be estimated using standard statistical software packages for random effects models or multilevel models, such as SAS, Stata, and MLwiN [7, 24, 25].

Statistical models for network meta-analysis become more complex, when some of the included studies have more than 2 treatment arms. This is because the differences in treatment effects within a study with multiple arms are not independent. Currently, a Bayesian approach to network meta-analysis developed by researchers in the Bristol and Leicester Universities is the most popular approach in the literature and used for the analysis of our example data in the next section [26, 27]. The differences between non-Bayesian and Bayesian approaches are mainly computational (i.e., the statistical algorithms for obtaining the results) rather than conceptual (i.e., the basic statistical models are the same).

2.4. Bayesian Network Meta-Analyses

Bayesian network meta-analysis, also known as mixed treatments comparison, uses a Bayesian statistical framework for a synthesis of direct and indirect comparisons of different treatments [812, 14, 16]. In the Bayesian paradigm, prior beliefs about parameters in the models are specified and factored into the estimation. For example, the mean treatment effect may be specified as 0.5 mm and with a standard error of 2 mm. However, in most scenarios, a noninformative prior is usually specified, for example, the mean effect is zero with a extremely large standard error. Posterior distributions of model parameters are then derived from the prior information and observed data [28]. In the Bayesian network meta-analysis, noninformative prior is usually used to minimise the impact of prior information on final results, as evidence for supporting a specific treatment effect is generally lacking. A flat prior distribution such as a uniform distribution or a normal distribution with a large variance can be specified for a study on the difference in the therapeutic effects between two treatments; consequently, the posterior distributions were almost entirely derived from the observed data. For example, we can specify that the prior distribution of log hazard ratio in implant survival between two treatments for peri-implantitis follows a normal distribution with zero mean and variance of 10,000. Suppose the observed variance of the difference between periodontal treatments is usually around 3 and 5, within which our prior distribution will consequently look flat and is therefore noninformative. As the probability distribution within the range of possible values is the same, the posterior distribution for the difference in log hazard ratio is mainly determined by the observed data.

In Bayesian analysis, posterior distributions are usually quite complex, so software packages use simulations-based algorithms known as Markov Chain Monte Carlo method to derive the approximate posterior probability distributions. Markov Chain Monte Carlo method starts with a set of initial values and then runs an iteration process to obtain the approximate posterior distribution. Samples are then taken from these posterior distributions for calculating each parameter in the model. Because Bayesian approach is a simulations-based methodology, it also has several other advantages. For instance, it can estimate predicted treatment effects based on the observed data, and it can provide ranking for treatments, which is especially useful when the differences between treatments are small. The statistical software for Bayesian approach is also more flexible than standard software in adapting to each unique situation where, for example, some studies have more than two treatment arms and where studies have different designs, such as parallel-group and split-mouth design.

The downside to Bayesian approach is that the statistical theory and estimation method for Bayesian network meta-analysis are mathematically advanced, and the software for Bayesian analysis, such as WinBUGS, has a steep learning curve. The website of the department of community-based medicine in Bristol University ( contains many WinBUGS code examples for network meta-analysis, and researchers can modify those codes for their analysis.

3. Network Meta-Analysis in Practice
3.1. Example Data

In this section, we used an example to illustrate how to undertake a network meta-analysis. We recently conducted a systematic review for the effectiveness of guided tissue regeneration (GTR), enamel matrix derivatives (EMD), and their combination therapies on the treatment of periodontal infrabony lesions [16]. In this tutorial, we used a subgroup of RCTs that compared GTR with nonresorbable or resorbable membranes to flap operation and that compared GTR with different types of membranes. The literature search strategy and quality assessment of included studies can be found in our previous publication. The outcome variable for our illustration is change in clinical attachment level (CAL), and we found 18 RCTs that compared at least two of the three treatments (flap operation, GTR with nonresorbable membranes, and GTR with resorbable membranes) [2946]. One study [46] was then excluded, because it did not report the standard errors for the treatment effects for different GTR treatment groups. One study [35] had two GTR treatment groups with nonresorbable membranes, and results from the two groups were combined into one. Of the 17 studies, only one study [36] compared all three treatment groups. Table 1 provided a summary for the 17 studies included in the final network meta-analysis.

3.2. Traditional Pairwise Comparisons

Traditional pairwise comparisons only use the direct evidence, and they should be undertaken in order to evaluate the consistency in direct and indirect comparisons. We used statistical software Stata (Version 12, StataCorp, College Station, TX, USA) for the analysis, and results were shown in Figure 2. Six studies compared GTR with nonresorbable membrane (GTR-N) to flap operation, and results from random effects meta-analysis showed GTR-N achieved 1.99 mm (95% confidence intervals (CI): 1.02 to 2.95) greater CAL gain than flap operation. Twelve studies compared GTR with resorbable membranes (GTR-R) to flap operation, and results from random effects meta-analysis showed GTR-R achieved 1 mm (95% confidence intervals (CI): 0.61 to 1.39) greater CAL gain than flap operation. Both meta-analyses showed substantial heterogeneity: the Cochrane-Q test is statistically significant (P < 0.001), and the I-squared was 76% and 85%, respectively. Funnel plot and Egger test suggested there might be small study bias in the comparison between GTR-R and flap operation (Figure 3). Only one study compares the two GTR treatments, and its results showed that GTR-N achieved 0.6 mm (95%CI: −0.44 to 1.64) greater CAL gain than GTR-R.

3.3. Bayesian Network Meta-Analysis

Bayesian network meta-analysis was then undertaken using the software WinBUGS (MRC Biostatistics Unit, Cambridge, England). WinBUGS codes used in our analysis were a modification of codes available on the website of the department of community-based medicine in Bristol University to accommodate continuous outcomes and studies with split-mouth design. Noninformative priors were used throughout the analyses. Markov Chain Monte Carlo method with 50,000 burn-in and further 50,000 simulations and with three chains of different initial values (i.e., 150,000 simulations in total) was used to obtain medians and 95% credible intervals (i.e., the 2.5 and 97.5 percentiles of simulation results), which may be interpreted as the likely range of the estimated parameter by excluding the extreme values. Results from the Bayesian network meta-analysis using the 17 studies were similar to those from the traditional pairwise comparison: GTR-N and GTR-R achieved 1.88 mm (95% credible intervals (CrI): 1.15 to 2.63) and 0.99 mm (95% CrI: 0.48 to 1.52) greater CAL gain than flap operation, respectively; GTR-N achieved 0.88 mm (95% CrI: 0.09 to 1.78) greater CAL gain than GTR-R. Figure 4 provided comparisons between results from the Bayesian and traditional meta-analysis.

3.4. Evaluating the Inconsistency between Direct and Indirect Evidence

Figure 4 showed that the three treatments in our network formed a loop, and, for every loop, it was possible to evaluate the consistency between direct and indirect evidence. For example, results from the single trial comparing GTR-N to GTR-R are direct comparison, whilst results from the traditional pairwise meta-analysis of the 6 trials comparing GTR-N to flap operation and those from the 12 trials comparing GTR-R to flap operation provide indirect comparisons between GTR-N and GTR-R by using flap operation as the reference treatment [47]. We denote the difference in CAL gain for comparing GTR-N to flap operation as dN-F, the difference in CAL gain for comparing GTR-R to flap operation as dR-F, and the difference in CAL gain for comparing GTR-N to GTR-R as dN-R. The indirect comparison between GTR-N and GTR-R is therefore dN-FdR-F = 1.99 − 1 = 0.99 = dN-RInd. The inconsistency is the difference between dN-R and dN-RInd: δ = dN-RdN-RInd = 0.99 − 0.6 = 0.39. A simple statistical test for evaluating the inconsistency is [47]:

[Formula ID: eq3]
where z is the ratio of δ over its standard error σs and follows a normal distribution. The variance σδ2 can be estimated by σδ2 = σdN-F2 + σdR-F2 + σdN-R2, where σdN-F2, σdR-F2, and σdN-R2 are variances of dN-F, dR-F, and dN-R, respectively. Using the results from Figure 2
[Formula ID: eq4]
The P value for z = 0.52 was 0.603, indicating that the inconsistency in direct and direct evidence was not significant.

Note that, for any loop, results of testing inconsistency remain the same, irrespective of the reference group chosen from the loop.

3.5. Ranking for the Treatments

Because Markov Chain Monte Carlo method for estimation used by Bayesian analysis is a simulation-based approach, we can calculate the rank for each treatment according its performance in each simulation [48]. In 98.3% of simulations, GTR-N ranked the best amongst the three treatments, and, in 1.7% of simulations, GTR-R ranked the best; this is consistent with results for point estimates and their credible intervals. Information about Ranking is especially useful when the number of treatments in the network meta-analysis is large and the differences in their treatment effects are small. Figure 5 shows the treatment rankings for all three treatments.

4. Practical Issues in Conducting a Network Meta-Analysis

As shown in our example, the main difference between a network meta-analysis and multiple pairwise meta-analyses for comparisons of multiple treatments is that the former use both direct and indirect evidence whilst the latter only use the direct evidence. All meta-analyses require comprehensive literature search, careful evaluation of available studies, and attentions to potential biases and heterogeneity. In this section, we discussed a few practical issues that may arise in conducting a network meta-analysis in dental research and provided some recommendations on how to deal with those issues.

4.1. Inclusion Criteria for Relevant Studies Need to Be Clearly Explained

Decisions on which studies should be included in the network meta-analysis are not always straightforward when undertaking network meta-analysis, because indirect evidence can be very broad [49, 50]. In our example, we included RCTs that compared at least two of the three treatments, GTR-N, GTR-R, and flap operation with the latter as the reference group. However, in terms of indirect comparisons, studies that contained one of even none of the three treatments could also be included. For example, studies that compared GTR-N to enamel matrix derivatives (EMD) or EMD to flap operation provided indirect evidence for comparing GTR-N with flap operation. Consequently, almost all RCTs on the treatment of periodontal infrabony lesions might be included in the network meta-analysis, and a practical decision has to be made for the inclusion criteria. This is why we decided that only studies that compared at least two of the three treatments were included. If the definition for relevant studies is too broad, the number of included studies will be large and results from network meta-analysis may be difficult to interpret due to the excessive heterogeneity and inconsistency in the evidence. The definition for relevant studies needs to be based on clinical knowledge; for instance, treatments or drugs that are either no longer used or available may be excluded. However, for a group of treatments within a network meta-analysis, the literature search should be comprehensive so that all eligible studies are included.

4.2. Data from Trials with Multiple Arms Should Be Appropriately Analysed

When there are more than two treatments in a trial, the study-specific treatment effects are unlikely to be independent; for example, suppose a trial has three treatment arms, GTR-N, GTR-R, and flap operation, and they are carried out by experienced periodontists. Consequently, treatment effects of both GTR-N and GTR-R compared to flap operation are likely to be greater than those in a trial where treatments are carried out by a periodontist in training. Special care has to be taken to avoid using the same control group more than once in estimating the differences in treatment effects between the test groups and the control group [25]. In our example, one study has three treatment arms, and it was assumed that the correlation between the two treatment effects differences (i.e., flap operation versus GTR-N, and flap operation versus GTR-R) was 0.5 following the suggestion by Lu and Ades [27]. The impact on the network meta-analysis of disregarding the correlations among treatment effects depends on the number of studies with more than two treatment arms and the strength of those correlations.

4.3. Possible Reasons for Any Observed Discrepancies between Direct and Indirect Evidence Should Be Investigated

In our example, there is no significant inconsistency in direct and indirect evidence, and, consequently, the discrepancy between results from traditional pairwise and Bayesian network meta-analyses is small. If the inconsistency test is significant, the discrepancy is likely to be large, as results from the Bayesian analysis are a combination of direct and indirect evidence. Substantial discrepancies usually indicate the heterogeneity, and similarity assumptions as discussed in Section 2.1 may be questionable, and researchers need to investigate the sources of heterogeneity. For instance, suppose treatment effects are related to baseline disease severity; if patients in A versus placebo trials have more severe baseline disease than those in B versus placebo trials, indirect comparisons will show that A seems to have greater treatment effects than B, even if there is no difference between A and B. In other scenarios, direct evidence comparing A with B may have a dubious quality and suffer a greater bias; consequently, indirect evidence becomes more reliable [51]. Heterogeneity is an issue that should be investigated in any meta-analysis (including both pairwise and network meta-analyses), and, when there is inconsistency in direct and indirect evidence, characteristics of studies involved in comparisons should be carefully evaluated; if feasible, a meta-regression or subgroup analysis should be undertaken to explore the sources of heterogeneity [2123].

4.4. Missing Information May Be Imputed Using Simple Methods

The most common missing information encountered in conducting a meta-analysis in dental research is the standard errors for the mean treatment effects which are usually used as the weights for combining the treatment effects reported by different studies, when the outcomes are continuous variables such as CAL. For binary outcomes, such as success or survival, treatment effects and its confidence intervals are derived from the numbers of patients in different categories, for example, the numbers of patients with or without success in different treatment groups. When the outcome is a continuous variable, we need the mean and its standard error for meta-analysis. The most common scenario is that a study reported the mean treatment effects and their standard errors without reporting the difference in treatment effects and its confidence intervals. Table 2 shows results from a hypothetic study with two treatments to illustrate how to impute the missing standard errors.

The change in the outcome CAL for the test group is 4.3 mm with standard deviation 1.3 mm, and the change in the outcome CAL for the control group is 1.9 mm with standard deviation 1.1 mm. Suppose this study uses a parallel-group design and has 10 patients in each group; the mean difference in treatment effects between the test and control groups is 4.3 − 1.9 = 2.4, and its standard error (σD) can be obtained by using the following formula [52]:

[Formula ID: eq5]
[Formula ID: EEq3]
nT and nC are the number of patients in the treatment and control groups, respectively, and ST and SC are the standard deviations of treatment effects for the treatment and control groups, respectively. Using the information in Table 2, we can obtain the pooled standard deviation S:
[Formula ID: eq7]
The t-value for the mean difference in treatment effects between the test and control groups is therefore 2.4/0.54 = 4.44, and the P value is 0.0003.

In a study with parallel-group design, the two treatments effects are supposed to be independent, but, in a study with split-mouth design (e.g., two teeth of the same patient are randomly assigned to the test and control groups), the treatment effects are likely to be correlated [53] and (6) is no longer suitable for obtaining the pooled standard deviation S. Instead, we use the following formula to obtain S:

[Formula ID: EEq4]
where n is the sample size and r is the correlation coefficient between the two treatment effects. The only missing information is r, and we have to make an informed guess about it. Lesaffre et al. [53] suggested using r = 0.25 for split-mouth study. Using Table 2 and n = 10,
[Formula ID: eq9]
Sometimes, a study only reported the means and standard deviations for the baseline and follow-up measurements for each group, and we need to calculate the means and standard deviations for change in the outcome for both groups first before we can apply either (6) or (8). Suppose x1 and x2 are the baseline and follow-up CAL for the test group, and d is the difference in CAL between x1 and x2. The mean of d is the difference in the means of x1 and x2, and the variance of d(sD2) can be obtained using the following formula: sD2 = s12 + s22 − 2rs1s2, where s1 and s2 are the standard deviations for x1 and x2, respectively, and r is the correlation coefficient between x1 and x2. Again, we need to make an informed guess about r, and r = 0.5 seems to be a reasonable one [54].

Imputing missing values can increase the number of included studies in a meta-analysis, and this is especially useful for a network meta-analysis when the number of treatments in comparisons is large but the number of studies is relatively few.

5. Conclusion

Network meta-analysis is an extension of pairwise comparisons of treatments to comparisons of all available treatments by incorporating both direct and indirect evidence. This new methodology has become widely adopted by meta-analysts in medical research and has been proven to be a very useful tool for evidence synthesis. The use of more sophisticated statistical approaches such as network meta-analysis can improve the efficiency in comparative effectiveness research and in the quality of decisions making. This tutorial aims to bring this new methodology to the attentions of dental researchers and to facilitate its adoption but also highlight several important issues in conducting and interpreting a network meta-analysis. Further information and technical details can be found in [3, 4, 2527]. The statistical theory behind network meta-analysis is nevertheless complex, so we strongly encourage close collaboration between dental researchers and experienced statisticians when planning and conducting a network meta-analysis.

Conflict of Intetrests

The authors declare that they have no conflict of interests.


The first author was funded by the United Kingdom government's Higher Education Funding Council for England (HEFCE).

1. Ades AE,Sculpher M,Sutton A,et al. Bayesian methods for evidence synthesis in cost-effectiveness analysisPharmacoEconomicsYear: 20062411192-s2.0-3204445466416445299
2. Sutton A,Ades AE,Cooper N,Abrams K. Use of indirect and mixed treatment comparisons for technology assessmentPharmacoEconomicsYear: 20082697537672-s2.0-5114909560318767896
3. Hoaglin DC,Hawkins N,Jansen JP,et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2Value in HealthYear: 20111444294372-s2.0-7995996049321669367
4. Jansen JP,Fleurence R,Devine B,et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1Value in HealthYear: 20111444174282-s2.0-7995992578721669366
5. Lumley T. Network meta-analysis for indirect treatment comparisonsStatistics in MedicineYear: 20022116231323242-s2.0-003719983712210616
6. Psaty BM,Lumley T,Furberg CD,et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysisJAMAYear: 200328919253425442-s2.0-003831228712759325
7. Glenny AM,Altman DG,Song F,et al. Indirect comparisons of competing interventionsHealth Technology AssessmentYear: 200592611342-s2.0-3364465309216014203
8. Cipriani A,Furukawa TA,Salanti G,et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisThe LancetYear: 200937396657467582-s2.0-60849086169
9. Phung OJ,Scholle JM,Talwar M,Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetesJAMAYear: 201030314141014182-s2.0-7795089108520388897
10. Coleman CI,Baker WL,Kluger J,White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trialsJournal of HypertensionYear: 20082646226292-s2.0-4044911909318327066
11. Cipriani A,Barbui C,Salanti G,et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysisThe LancetYear: 20113789799130613152-s2.0-80053925799
12. Chang KV,Chen SY,Chen WS,Tu YK,Chien KL. Comparative effectiveness of focused shock wave therapy of different intensity levels and radial shock wave therapy for treating plantar fasciitis: a systematic review and network meta-analysis Archives of Physical Medicine & Rehabilitation. In press.
13. Tu YK,Woolston A,Faggion CM. Do bone grafts or barrier membranes provide additional treatment effects for infrabony lesions treated with enamel matrix derivatives? A network meta-analysis of randomized-controlled trialsJournal of Clinical PeriodontologyYear: 201037159792-s2.0-7254909308619958442
14. Wong MCM,Clarkson J,Glenny AM,et al. Cochrane reviews on the benefits/risks of fluoride toothpastesJournal of Dental ResearchYear: 20119055735792-s2.0-7995585410521248357
15. Faggion Jr CM,Chambrone L,Listl S,Tu Y-K. Network meta-analysis for evaluating interventions in implant dentistry: the case of peri-implantitis treatment Clinical Implant Dentistry & Related Research. In press. 2-s2.0-80051600241
16. Tu Y-K,Needleman I,Chambrone L,Lu H-K,Faggion CM Jr.. A bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapiesJournal of Clinical PeriodontologyYear: 20123933033142-s2.0-8485659811822393565
17. Song F,Altman DG,Glenny AM,Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJYear: 200332673874724752-s2.0-003737400812609941
18. Song F,Xiong T,Parekh-Bhurke S,et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological studyBMJYear: 20113437821, article 4722-s2.0-84859007944
19. Li T,Puhan MA,Vedula SS,Singh S,Dickersin K. Network meta-analysis—highly attractive but more methodological research is neededBMC MedicineYear: 20119, article 792-s2.0-79959536051
20. Donegan S,Williamson P,Gamble C,Tudur-Smith C. Indirect comparisons: a review of reporting and methodological qualityPLoS ONEYear: 20105112-s2.0-78649754570e11054
21. Dias S,Welton NJ,Caldwell DM,Ades AE. Checking consistency in mixed treatment comparison meta-analysisStatistics in MedicineYear: 2010297-89329442-s2.0-7794942004220213715
22. Salanti G,Higgins JPT,Ades AE,Ioannidis JPA. Evaluation of networks of randomized trialsStatistical Methods in Medical ResearchYear: 20081732793012-s2.0-4674915495117925316
23. Salanti G,Marinho V,Higgins JPT. A case study of multiple-treatments meta-analysis demonstrates that covariates should be consideredJournal of Clinical EpidemiologyYear: 20096288578642-s2.0-6764930308219157778
24. Whitehead A. Meta-Analysis of Controlled Clinical TrialsYear: 2002Chichester, UKJohn Wiley & Sons
25. Jones B,Roger J,Lane PW,et al. Statistical approaches for conducting network meta-analysis in drug developmentPharmaceutical StatisticsYear: 20111065235312-s2.0-8485516650922213533
26. Lu G,Ades AE. Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in MedicineYear: 20042320310531242-s2.0-504422141615449338
27. Lu G,Ades AE. Assessing evidence inconsistency in mixed treatment comparisonsJournal of the American Statistical AssociationYear: 20061014744474592-s2.0-33745663057
28. Ntzoufras I. Bayesian Modeling Using WinBUGSYear: 2009New Jersey, NJ, USAJohn Wiley & Sons
29. Sculean A,Windisch P,Chiantella GC,Donos N,Brecx M,Reich E. Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration: a prospective controlled clinical studyJournal of Clinical PeriodontologyYear: 20012853974032-s2.0-003534497511350501
30. Silvestri M,Ricci G,Rasperini G,Sartori S,Cattaneo V. Comparison of treatments of infrabony defects with Enamel Matrix Derivative, Guided Tissue Regeneration with a nonresorbable membrane and Widman Modified Flap: a pilot studyJournal of Clinical PeriodontologyYear: 20002786036102-s2.0-003424191110959787
31. Zucchelli G,Bernardi F,Montebugnoli L,De Sanctis M. Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trialJournal of PeriodontologyYear: 20027313122-s2.0-003620083611846197
32. Mayfield L,Söderholm G,Hallström H,et al. Guided tissue regeneration for the treatment of intraosseous defects using a biabsorbable membrane. A controlled clinical studyJournal of Clinical PeriodontologyYear: 19982575855952-s2.0-00321105149696260
33. Tonetti MS,Cortellini P,Suvan JE,et al. Generalizability of the added benefits of guided tissue regeneration in the treatment of deep intrabony defects. Evaluation in a multi-center randomized controlled clinical trialJournal of PeriodontologyYear: 19986911118311922-s2.0-00322006169848527
34. Cortellini P,Tonetti MS,Lang NP,et al. The simplified papilla preservation flap in the regenerative treatment of deep intrabony defects: clinical outcomes and postoperative morbidityJournal of PeriodontologyYear: 20017212170217122-s2.0-003569402611811506
35. Cortellini P,Pini Prato G,Tonetti MS. Periodontal regeneration of human intrabony defects with titanium reinforced membranes. A controlled clinical trialJournal of PeriodontologyYear: 19956697978032-s2.0-00293650187500246
36. Cortellini P,Prato GP,Tonetti MS. Periodontal regeneration of human intrabony defects with bioresorbable membranes. A controlled clinical trialJournal of PeriodontologyYear: 19966732172232-s2.0-00300987548708952
37. Paolantonio M,Perinetti G,Dolci M,et al. Surgical treatment of periodontal intrabony defects with calcium sulfate implant and barrier versus collagen barrier or open flap debridement alone: a 12-month randomized controlled clinical trialJournal of PeriodontologyYear: 20087910188618932-s2.0-5354912553218834243
38. Stavropoulos A,Karring ES,Kostopoulos L,Karring T. Deproteinized bovine bone and gentamicin as an adjunct to GTR in the treatment of intrabony defects: a randomized controlled clinical studyJournal of Clinical PeriodontologyYear: 20033064864952-s2.0-004238290612795786
39. Blumenthal N,Steinberg J. The use of collagen membrane barriers in conjunction with combined demineralized bone-collagen gel implants in human infrabony defectsJournal of PeriodontologyYear: 19906163193272-s2.0-00254413352366139
40. Pritlove-Carson S,Palmer RM,Floyd PD. Evaluation of guided tissue regeneration in the treatment of paired periodontal defectsBritish Dental JournalYear: 1995179103883942-s2.0-00296522068519562
41. Ratka-Krüger P,Neukranz E,Raetzke P. Guided tissue regeneration procedure with bioresorbable membranes versus conventional flap surgery in the treatment of infrabony periodontal defectsJournal of Clinical PeriodontologyYear: 20002721201272-s2.0-003413416310703658
42. Loos BG,Louwerse PHG,Van Winkelhoff AJ,et al. Use of barrier membranes and systemic antibiotics in the treatment of intraosseous defectsJournal of Clinical PeriodontologyYear: 200229109109212-s2.0-003678260112445223
43. Cortellini P,Carnevale G,Sanz M,Tonetti MS. Treatment of deep and shallow intrabony defects. A multicenter randomized controlled clinical trialJournal of Clinical PeriodontologyYear: 199825129819872-s2.0-00322482109869347
44. Chung KM,Salkin LM,Stein MD,Freedman AL. Clinical evaluation of a biodegradable collagen membrane in guided tissue regenerationJournal of PeriodontologyYear: 199061127327362-s2.0-00255827752269914
45. Mora F,Etienne D,Ouhayoun JP. Treatment of interproximal angular defects by Guided Tissue Regeneration: 1 year follow-upJournal of Oral RehabilitationYear: 19962395996062-s2.0-00302290658890060
46. Pontoriero R,Wennström J,Lindhe J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects: a prospective controlled clinical studyJournal of Clinical PeriodontologyYear: 199926128338402-s2.0-003325272510599912
47. Bucher HC,Guyatt GH,Griffith LE,Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical EpidemiologyYear: 19975066836912-s2.0-00307931209250266
48. Salanti G,Ades AE,Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJournal of Clinical EpidemiologyYear: 20116421631712-s2.0-7865050965120688472
49. Edwards SJ,Borrill J. Network meta-analysis: importance of appropriate trial selectionValue in HealthYear: 20101356816822-s2.0-7795538179520345543
50. Hawkins N,Scott DA,Woods BS,Thatcher N. No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant dataValue in HealthYear: 200912699610032-s2.0-6765120879619402854
51. Madan J,Stevenson MD,Cooper KL,Ades AE,Whyte S,Akehurst R. Consistency between direct and indirect trial evidence: is direct evidence always more reliable?Value in HealthYear: 20111469539602-s2.0-8005270823221914518
52. Kirkwood B,Sterne JAE. Essential Medical StatisticsYear: 2003London, UKBlackwell
53. Lesaffre E,Philstrom B,Needleman I,Worthington H. The design and analysis of split-mouth studies: what statisticians and clinicians should knowStatistics in MedicineYear: 20092828347034822-s2.0-7044970335019536744
54. Tu YK,Bælum V,Gilthorpe MS. The problem of analysing the relationship between change and initial value in oral health researchEuropean Journal of Oral SciencesYear: 200511342712782-s2.0-2384451149316048518

Article Categories:
  • Review Article

Previous Document:  Tooth surface loss and associated risk factors in northern saudi arabia.
Next Document:  Thyroid and Hepatic Haemodynamic Alterations among Egyptian Children with Liver Cirrhosis.